Free tool
FAERS Monitor: Austedo Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216354 or its brand name (Austedo Xr, Deutetrabenazine). Reports on generic versions are filed under their own applications.
Reports
2,016
Serious
1,213
60% of reports
Hospitalization
322
Death reported
159
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective320
- depression183
- product use issue176
- dyskinesia156
- somnolence146
- fatigue136
- death131
- product use in unapproved indication131
- suicidal ideation119
- tremor118
- fall115
- tardive dyskinesia113
- insomnia104
- dizziness100
- off label use90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 15 |
| 2023 | 59 |
| 2024 | 485 |
| 2025 | 734 |
| 2026 | 701 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,143 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tardive dyskinesiaSignal | 113 | 42.0 | 35.1 | 4,465 |
| dyskinesiaSignal | 156 | 40.2 | 34.6 | 5,912 |
| suicidal ideationSignal | 119 | 13.6 | 11.4 | 1,378 |
| product use issueSignal | 176 | 9.8 | 8.5 | 1,389 |
| depressionSignal | 183 | 8.4 | 7.3 | 1,197 |
| somnolenceSignal | 146 | 7.6 | 6.5 | 833 |
| tremorSignal | 118 | 7.4 | 6.2 | 654 |
| product use in unapproved indicationSignal | 131 | 5.5 | 4.7 | 485 |
| insomniaSignal | 104 | 4.1 | 3.4 | 241 |
| fallSignal | 115 | 3.6 | 3.0 | 217 |
| drug ineffectiveSignal | 320 | 2.5 | 2.3 | 315 |
| dizzinessSignal | 100 | 2.1 | 1.7 | 57 |
| fatigue | 136 | 1.8 | 1.5 | 52 |
| death | 131 | 1.6 | 1.3 | 29 |
| off label use | 90 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.